Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition

Lymphangioleiomyomatosis (LAM) is a rare disease involving cystic lung destruction by invasive LAM cells. These cells harbor loss‐of‐function mutations in TSC2, conferring hyperactive mTORC1 signaling. Here, tissue engineering tools are employed to model LAM and identify new therapeutic candidates....

Descripción completa

Detalles Bibliográficos
Autores principales: Pietrobon, Adam, Yockell‐Lelièvre, Julien, Melong, Nicole, Smith, Laura J., Delaney, Sean P., Azzam, Nadine, Xue, Chang, Merwin, Nishanth, Lian, Eric, Camacho‐Magallanes, Alberto, Doré, Carole, Musso, Gabriel, Julian, Lisa M., Kristof, Arnold S., Tam, Roger Y., Berman, Jason N., Shoichet, Molly S., Stanford, William L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502849/
https://www.ncbi.nlm.nih.gov/pubmed/37400371
http://dx.doi.org/10.1002/advs.202302611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502849/
https://www.ncbi.nlm.nih.gov/pubmed/37400371
http://dx.doi.org/10.1002/advs.202302611

Ejemplares similares